Modulation of striatal neuron activity by cyclic nucleotide signalling and phosphodiesterase inhibition

Basal Ganglia

Volumn 3, Issue 3, 2013, Pages 137-146

  Threlfell, Sarah ^a   West, Anthony R ^b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

Author keywords

Cyclic AMP; Cyclic GMP; Electrophysiology; Phosphodiesterase

Indexed keywords

1H 1,2,4 OXADIAZOLO[4,3 A]QUINOXALIN 1 ONE; 2 [4 [1 METHYL 4 (4 PYRIDINYL) 3 PYRAZOLYL]PHENOXYMETHYL]QUINOLINE; BAY 60 7550; BAY 607550; BAY 736691; CILOSTAMIDE; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC AMP DEPENDENT PROTEIN KINASE INHIBITOR; CYCLIC GMP; CYCLIC NUCLEOTIDE; DOPAMINE 2 RECEPTOR; GLUTAMIC ACID; IC 224; LEVODOPA; MESSENGER RNA; MILRINONE; PAPAVERINE; PF 4447943; PF 545920; PHOSPHODIESTERASE; PHOSPHODIESTERASE 10 INHIBITOR; PHOSPHODIESTERASE INHIBITOR; PQ 10; ROLIPRAM; TP 10; UNCLASSIFIED DRUG; VINPOCETINE;

BRAIN NERVE CELL; CATALEPSY; CELL ACTIVITY; CORPUS STRIATUM; DOPAMINERGIC TRANSMISSION; DYSKINESIA; ENZYME INHIBITION; HUMAN; HUNTINGTON CHOREA; INTRACELLULAR SIGNALING; LONG TERM DEPRESSION; LONG TERM POTENTIATION; MEMORY DISORDER; MOTOR DYSFUNCTION; NERVE CELL EXCITABILITY; NERVE CELL PLASTICITY; NEUROMODULATION; NEUROPATHOLOGY; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME;

EID: 84888876330     PISSN: 22105336     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.baga.2013.08.001     Document Type: Review

References (117)

1. Greengard P. The neurobiology of slow synaptic transmission. Science 2001, 294(5544):1024-1030.
2. 2+-sensitive adenylyl cyclases, key integrators of cellular signalling. Life Sci 1998, 62(17-18):1647-1652.
3. Boehning D., Snyder S.H. Novel neural modulators. Annu Rev Neurosci 2003, 26:105-131.
4. Bredt D.S. Nitric oxide signaling specificity-the heart of the problem. J Cell Sci 2003, 116(Pt 1):9-15.
5. Garthwaite J. Concepts of neural nitric oxide-mediated transmission. Eur J Neurosci 2008, 27(11):2783-2802.
6. Bredt D.S., Hwang P.M., Snyder S.H. Localization of nitric oxide synthase indicating a neural role for nitric oxide. Nature 1990, 347(6295):768-770.
7. Bredt D.S., Snyder S.H. Isolation of nitric oxide synthetase: a calmodulin-requiring enzyme. Proc Natl Acad Sci U S A 1990, 87(2):682-685.
8. de Vente J., Markerink-van Ittersum M., van Abeelen J., Emson P.C., Axer H., Steinbusch H.W. NO-mediated cGMP synthesis in cholinergic neurons in the rat forebrain: effects of lesioning dopaminergic or serotonergic pathways on nNOS and cGMP synthesis. Eur J Neurosci 2000, 12(2):507-519.
9. Hope B.T., Michael G.J., Knigge K.M., Vincent S.R. Neuronal NADPH diaphorase is a nitric oxide synthase. Proc Natl Acad Sci U S A 1991, 88(7):2811-2814.
10. Vincent S.R., Das S., Maines M.D. Brain heme oxygenase isoenzymes and nitric oxide synthase are co-localized in select neurons. Neuroscience 1994, 63(1):223-231.
11. Murad F. Shattuck lecture nitric oxide and cyclic GMP in cell signaling and drug development. N Engl J Med 2006, 355(19):2003-2011.
12. Lugnier C. Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents. Pharmacol Ther 2006, 109(3):366-398.
13. Menniti F.S., Faraci W.S., Schmidt C.J. Phosphodiesterases in the CNS: targets for drug development. Nat Rev Drug Discov 2006, 5(8):660-670.
14. Bender A.T., Beavo J.A. Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol Rev 2006, 58(3):488-520.
15. Omori K., Kotera J. Overview of PDEs and their regulation. Circ Res 2007, 100(3):309-327.
16. Kleppisch T. Phosphodiesterases in the central nervous system. Handb Exp Pharmacol 2009, (191):71-92.
17. Deisseroth K., Bito H., Tsien R.W. Signaling from synapse to nucleus: postsynaptic CREB phosphorylation during multiple forms of hippocampal synaptic plasticity. Neuron 1996, 16(1):89-101.
18. Deisseroth K., Tsien R.W. Dynamic multiphosphorylation passwords for activity-dependent gene expression. Neuron 2002, 34(2):179-182.
19. Frank D.A., Greenberg M.E. CREB: a mediator of long-term memory from mollusks to mammals. Cell 1994, 79(1):5-8.
20. Nishi A., Watanabe Y., Higashi H., Tanaka M., Nairn A.C., Greengard P. Glutamate regulation of DARPP-32 phosphorylation in neostriatal neurons involves activation of multiple signaling cascades. Proc Natl Acad Sci U S A 2005, 102(4):1199-1204.
21. Tsou K., Snyder G.L., Greengard P. Nitric oxide/cGMP pathway stimulates phosphorylation of DARPP-32: a dopamine- and cAMP-regulated phosphoprotein, in the substantia nigra. Proc Natl Acad Sci U S A 1993, 90(8):3462-3465.
22. Calabresi P., Picconi B., Tozzi A., Di Filippo M. Dopamine-mediated regulation of corticostriatal synaptic plasticity. Trends Neurosci 2007, 30(5):211-219.
23. Del Bel E.A., Guimaraes F.S., Bermudez-Echeverry M., Gomes M.Z., Schiaveto-de-souza A., Padovan-Neto F.E., et al. Role of nitric oxide on motor behavior. Cell Mol Neurobiol 2005, 25(2):371-392.
24. Colwell C.S., Levine M.S. Excitatory synaptic transmission in neostriatal neurons: regulation by cyclic AMP-dependent mechanisms. J Neurosci 1995, 15(3 Pt 1):1704-1713.
25. Threlfell S., Sammut S., Menniti F.S., Schmidt C.J., West A.R. Inhibition of phosphodiesterase 10A increases the responsiveness of striatal projection neurons to cortical stimulation. J Pharmacol Exp Ther 2009, 328(3):785-795.
26. West A.R., Grace A.A. The nitric oxide-guanylyl cyclase signaling pathway modulates membrane activity states and electrophysiological properties of striatal medium spiny neurons recorded in vivo. J Neurosci 2004, 24(8):1924-1935.
27. Sammut S., Threlfell S., West A.R. Nitric oxide-soluble guanylyl cyclase signaling regulates corticostriatal transmission and short-term synaptic plasticity of striatal projection neurons recorded in vivo. Neuropharmacology 2010, 58(3):624-631.
28. Tseng K.Y., Snyder-Keller A., O'Donnell P. Dopaminergic modulation of striatal plateau depolarizations in corticostriatal organotypic cocultures. Psychopharmacology (Berl) 2007, 191(3):627-640.
29. Brady A.M., O'Donnell P. Dopaminergic modulation of prefrontal cortical input to nucleus accumbens neurons in vivo. J Neurosci 2004, 24(5):1040-1049.
30. Cepeda C., Buchwald N.A., Levine M.S. Neuromodulatory actions of dopamine in the neostriatum are dependent upon the excitatory amino acid receptor subtypes activated. Proc Natl Acad Sci U S A 1993, 90(20):9576-9580.
31. Chergui K., Lacey M.G. Modulation by dopamine D1-like receptors of synaptic transmission and NMDA receptors in rat nucleus accumbens is attenuated by the protein kinase C inhibitor Ro 32-0432. Neuropharmacology 1999, 38(2):223-231.
32. Levine M.S., Li Z., Cepeda C., Cromwell H.C., Altemus K.L. Neuromodulatory actions of dopamine on synaptically-evoked neostriatal responses in slices. Synapse 1996, 24(1):65-78.
33. Snyder G.L., Fienberg A.A., Huganir R.L., Greengard P. A dopamine/D1 receptor/protein kinase A/dopamine- and cAMP-regulated phosphoprotein (Mr 32kDa)/protein phosphatase-1 pathway regulates dephosphorylation of the NMDA receptor. J Neurosci 1998, 18(24):10297-10303.
34. Jocoy E.L., Andre V.M., Cummings D.M., Rao S.P., Wu N., Ramsey A.J., et al. Dissecting the contribution of individual receptor subunits to the enhancement of N-methyl-d-aspartate currents by dopamine D1 receptor activation in striatum. Front Syst Neurosci 2011, 5:28.
35. West A.R., Galloway M.P., Grace A.A. Regulation of striatal dopamine neurotransmission by nitric oxide: effector pathways and signaling mechanisms. Synapse 2002, 44(4):227-245.
36. Calabresi P., Centonze D., Gubellini P., Marfia G.A., Bernardi G. Glutamate-triggered events inducing corticostriatal long-term depression. J Neurosci 1999, 19(14):6102-6110.
37. Gittis A.H., Nelson A.B., Thwin M.T., Palop J.J., Kreitzer A.C. Distinct roles of GABAergic interneurons in the regulation of striatal output pathways. J Neurosci 2010, 30(6):2223-2234.
38. Ibanez-Sandoval O., Tecuapetla F., Unal B., Shah F., Koos T., Tepper J.M. A novel functionally distinct subtype of striatal neuropeptide Y interneuron. J Neurosci 2011, 31(46):16757-16769.
39. Ondracek J.M., Dec A., Hoque K.E., Lim S.A., Rasouli G., Indorkar R.P., et al. Feed-forward excitation of striatal neuron activity by frontal cortical activation of nitric oxide signaling in vivo. Eur J Neurosci 2008, 27(7):1739-1754.
40. Sammut S., Park D.J., West A.R. Frontal cortical afferents facilitate striatal nitric oxide transmission in vivo via a NMDA receptor and neuronal NOS-dependent mechanism. J Neurochem 2007, 103(3):1145-1156.
41. Coskran T.M., Morton D., Menniti F.S., Adamowicz W.O., Kleiman R.J., Ryan A.M., et al. Immunohistochemical localization of phosphodiesterase 10A in multiple mammalian species. J Histochem Cytochem 2006, 54(11):1205-1213.
42. Sano H., Nagai Y., Miyakawa T., Shigemoto R., Yokoi M. Increased social interaction in mice deficient of the striatal medium spiny neuron-specific phosphodiesterase 10A2. J Neurochem 2008, 105(2):546-556.
43. Seeger T.F., Bartlett B., Coskran T.M., Culp J.S., James L.C., Krull D.L., et al. Immunohistochemical localization of PDE10A in the rat brain. Brain Res 2003, 985(2):113-126.
44. Xie Z., Adamowicz W.O., Eldred W.D., Jakowski A.B., Kleiman R.J., Morton D.G., et al. Cellular and subcellular localization of PDE10A: a striatum-enriched phosphodiesterase. Neuroscience 2006, 139(2):597-607.
45. Nishi A., Kuroiwa M., Miller D.B., O'Callaghan J.P., Bateup H.S., Shuto T., et al. Distinct roles of PDE4 and PDE10A in the regulation of cAMP/PKA signaling in the striatum. J Neurosci 2008, 28(42):10460-10471.
46. Strick C.A., James L.C., Fox C.B., Seeger T.F., Menniti F.S., Schmidt C.J. Alterations in gene regulation following inhibition of the striatum-enriched phosphodiesterase: PDE10A. Neuropharmacology 2010, 58(2):444-451.
47. Shen W., Flajolet M., Greengard P., Surmeier D.J. Dichotomous dopaminergic control of striatal synaptic plasticity. Science 2008, 321(5890):848-851.
48. Calabresi P., Gubellini P., Centonze D., Sancesario G., Morello M., Giorgi M., et al. A critical role of the nitric oxide/cGMP pathway in corticostriatal long-term depression. J Neurosci 1999, 2489-2499.
49. Doreulee N., Sergeeva O.A., Yanovsky Y., Chepkova A.N., Selbach O., Godecke A., et al. Cortico-striatal synaptic plasticity in endothelial nitric oxide synthase deficient mice. Brain Res 2003, 964(1):159-163.
50. Calabresi P., Gubellini P., Centonze D., Picconi B., Bernardi G., Chergui K., et al. Dopamine and cAMP-regulated phosphoprotein 32kDa controls both striatal long-term depression and long-term potentiation: opposing forms of synaptic plasticity. J Neurosci 2000, 20(22):8443-8451.
51. West A.R., Galloway M.P. Endogenous nitric oxide facilitates striatal dopamine and glutamate efflux in vivo: role of ionotropic glutamate receptor-dependent mechanisms. Neuropharmacology 1997, 36(11-12):1571-1581.
52. West A.R., Grace A.A. Striatal nitric oxide signaling regulates the neuronal activity of midbrain dopamine neurons in vivo. J Neurophysiol 2000, 83(4):1796-1808.
53. Charpier S., Deniau J.M. In vivo activity-dependent plasticity at cortico-striatal connections: evidence for physiological long-term potentiation. Proc Natl Acad Sci U S A 1997, 94(13):7036-7040.
54. Pare D., Shink E., Gaudreau H., Destexhe A., Lang E.J. Impact of spontaneous synaptic activity on the resting properties of cat neocortical pyramidal neurons in vivo. J Neurophysiol 1998, 79(3):1450-1460.
55. Calabresi P., Maj R., Pisani A., Mercuri N.B., Bernardi G. Long-term synaptic depression in the striatum: physiological and pharmacological characterization. J Neurosci 1992, 12(11):4224-4233.
56. Surmeier D.J., Plotkin J., Shen W. Dopamine and synaptic plasticity in dorsal striatal circuits controlling action selection. Curr Opin Neurobiol 2009, 19(6):621-628.
57. West A.R., Tseng K.Y. Nitric oxide-soluble guanylyl cyclase-cyclic GMP signaling in the striatum: new targets for the treatment of Parkinson's Disease?. Front Syst Neurosci 2011, 5:p55.
58. Benarroch E.E. HCN channels: function and clinical implications. Neurology 2013, 80(3):304-310.
59. Monteggia L.M., Eisch A.J., Tang M.D., Kaczmarek L.K., Nestler E.J. Cloning and localization of the hyperpolarization-activated cyclic nucleotide-gated channel family in rat brain. Brain Res Mol Brain Res 2000, 81(1-2):129-139.
60. Wilson C.J. The mechanism of intrinsic amplification of hyperpolarizations and spontaneous bursting in striatal cholinergic interneurons. Neuron 2005, 45(4):575-585.
61. Svenningsson P., Nishi A., Fisone G., Girault J.A., Nairn A.C., Greengard P. DARPP-32: an integrator of neurotransmission. Annu Rev Pharmacol Toxicol 2004, 44:269-296.
62. Surmeier D.J., Ding J., Day M., Wang Z., Shen W. D1, D2 dopamine-receptor modulation of striatal glutamatergic signaling in striatal medium spiny neurons. Trends Neurosci 2007, 30(5):228-235.
63. Munhoz C.D., Kawamoto E.M., de Sa Lima L., Lepsch L.B., Glezer I., Marcourakis T., et al. Glutamate modulates sodium-potassium-ATPase through cyclic GMP and cyclic GMP-dependent protein kinase in rat striatum. Cell Biochem Funct 2005, 23(2):115-123.
64. MacDonald M.E., Ambrose C.M., Duyao M.P., Myers R.H., Lin C., Srinidhi L., et al. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993, 72(6):971-983.
65. Andre V.M., Cepeda C., Levine M.S. Dopamine and glutamate in Huntington's disease: a balancing act. CNS Neurosci Ther 2010, 16(3):163-178.
66. Cepeda C., Bamford N.S., Andre V.M., Levine M.S. Alterations in corticostriatal synaptic function in Huntington's and Parkinson's diseases. Handbook of basal ganglia structure and function, a decade of progress 2010, 607-623. Elsevier Inc. Academic Press, London. H. Steiner, K.Y. Tseng (Eds.).
67. Andre V.M., Cepeda C., Fisher Y.E., Huynh M., Bardakjian N., Singh S., et al. Differential electrophysiological changes in striatal output neurons in Huntington's disease. J Neurosci 2011, 31(4):1170-1182.
68. Huntington Study Group Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology 2006, 66(3):366-372.
69. Gines S., Seong I.S., Fossale E., Ivanova E., Trettel F., Gusella J.F., et al. Specific progressive cAMP reduction implicates energy deficit in presymptomatic Huntington's disease knock-in mice. Hum Mol Genet 2003, 12(5):497-508.
70. Cramer H., Kohler J., Oepen G., Schomburg G., Schroter E. Huntington's chorea-measurements of somatostatin: substance P and cyclic nucleotides in the cerebrospinal fluid. J Neurol 1981, 225(3):183-187.
71. Cramer H., Warter J.M., Renaud B. Analysis of neurotransmitter metabolites and adenosine 3',5'-monophosphate in the CSF of patients with extrapyramidal motor disorders. Adv Neurol 1984, 40:431-435.
72. Norris P.J., Waldvogel H.J., Faull R.L., Love D.R., Emson P.C. Decreased neuronal nitric oxide synthase messenger RNA and somatostatin messenger RNA in the striatum of Huntington's disease. Neuroscience 1996, 72(4):1037-1047.
73. Haibei H., Elizabeth A.M., Andrea L.O.H., Geraldine T.G., Eileen M.D.-W. Mutant huntingtin affects the rate of transcription of striatum-specific isoforms of phosphodiesterase 10A. Eur J Neurosci 2004, 3351-3363.
74. Hebb A.L.O., Robertson H.A., Denovan-Wright E.M. Striatal phosphodiesterase mRNA and protein levels are reduced in Huntington's disease transgenic mice prior to the onset of motor symptoms. Neuroscience 2004, 123(4):967-981.
75. Leuti A., Laurenti D., Giampa C., Montagna E., Dato C., Anzilotti S., et al. Phosphodiesterase 10A (PDE10A) localization in the R6/2 mouse model of Huntington's disease. Neurobiol Dis 2013, 52:104-116.
76. Hu H., McCaw E.A., Hebb A.L., Gomez G.T., Denovan-Wright E.M. Mutant huntingtin affects the rate of transcription of striatum-specific isoforms of phosphodiesterase 10A. Eur J Neurosci 2004, 20(12):3351-3363.
77. Beal M.F., Swartz K.J., Finn S.F., Mazurek M.F., Kowall N.W. Neurochemical characterization of excitotoxin lesions in the cerebral cortex. J Neurosci 1991, 11(1):147-158.
78. Cicchetti F., Parent A. Striatal interneurons in Huntington's disease: selective increase in the density of calretinin-immunoreactive medium-sized neurons. Mov Disord 1996, 11(6):619-626.
79. Ferrante R.J., Kowall N.W., Beal M.F., Richardson E.P., Bird E.D., Martin J.B. Selective sparing of a class of striatal neurons in Huntington's disease. Science 1985, 230(4725):561-563.
80. Rajput P.S., Kharmate G., Norman M., Liu S.H., Sastry B.R., Brunicardi C.F., et al. Somatostatin receptor 1 and 5 double knockout mice mimic neurochemical changes of Huntington's disease transgenic mice. PLoS ONE 2011, 6(9):e24467.
81. Giampa C., Patassini S., Borreca A., Laurenti D., Marullo F., Bernardi G., et al. Phosphodiesterase 10 inhibition reduces striatal excitotoxicity in the quinolinic acid model of Huntington's disease. Neurobiol Dis 2009, 34(3):450-456.
82. Giampa C., Laurenti D., Anzilotti S., Bernardi G., Menniti F.S., Fusco F.R. Inhibition of the striatal specific phosphodiesterase PDE10A ameliorates striatal and cortical pathology in R6/2 mouse model of Huntington's disease. PLoS ONE 2010, 5(10):e13417.
83. Parkinson J. An essay on the shaking palsy. 1817. J Neuropsychiatry Clin Neurosci 2002, 14(2):223-236. [discussion 2].
84. Rodriguez-Oroz M.C., Jahanshahi M., Krack P., Litvan I., Macias R., Bezard E., et al. Initial clinical manifestations of Parkinson's disease: features and pathophysiological mechanisms. Lancet Neurol 2009, 8(12):1128-1139.
85. Albin R.L., Young A.B., Penney J.B. The functional anatomy of basal ganglia disorders. Trends Neurosci 1989, 12(10):366-375.
86. Kreitzer A.C., Malenka R.C. Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models. Nature 2007, 445(7128):643-647.
87. Obeso J.A., Grandas F., Vaamonde J., Luquin M.R., Artieda J., Lera G., et al. Motor complications associated with chronic levodopa therapy in Parkinson's disease. Neurology 1989, 39(11 (Suppl. 2)):11-19.
88. Calabresi P., Di Filippo M., Gallina A., Wang Y., Stankowski J.N., Picconi B., et al. New synaptic and molecular targets for neuroprotection in Parkinson's disease. Mov Disord 2013, 28(1):51-60.
89. Giorgi M., D'Angelo V., Esposito Z., Nuccetelli V., Sorge R., Martorana A., et al. Lowered cAMP and cGMP signalling in the brain during levodopa-induced dyskinesias in hemiparkinsonian rats: new aspects in the pathogenetic mechanisms. Eur J Neurosci 2008, 28(5):941-950.
90. Chalimoniuk M., Langfort J. The effect of subchronic: intermittent l-DOPA treatment on neuronal nitric oxide synthase and soluble guanylyl cyclase expression and activity in the striatum and midbrain of normal and MPTP-treated mice. Neurochem Int 2007, 50(6):821-833.
91. Chalimoniuk M., Langfort J., Lukacova N., Marsala J. Upregulation of guanylyl cyclase expression and activity in striatum of MPTP-induced parkinsonism in mice. Biochem Biophys Res Commun 2004, 324(1):118-126.
92. Altar C.A., Boyar W.C., Kim H.S. Discriminatory roles for D1 and D2 dopamine receptor subtypes in the in vivo control of neostriatal cyclic GMP. Eur J Pharmacol 1990, 181(1-2):17-21.
93. Siuciak J.A., Chapin D.S., Harms J.F., Lebel L.A., McCarthy S.A., Chambers L., et al. Inhibition of the striatum-enriched phosphodiesterase PDE10A: a novel approach to the treatment of psychosis. Neuropharmacology 2006, 51(2):386-396.
94. Tseng K.Y., Caballero A., Dec A., Cass D.K., Simak N., Sunu E.et al. Inhibition of striatal soluble guanylyl cyclase-cGMP signaling reverses basal ganglia dysfunction and akinesia in experimental parkinsonism. PLoS ONE 2011, 6(11):e27187.
95. Picconi B., Bagetta V., Ghiglieri V., Paille V., Di Filippo M., Pendolino V., et al. Inhibition of phosphodiesterases rescues striatal long-term depression and reduces levodopa-induced dyskinesia. Brain 2011, 134(Pt 2):375-387.
96. Picconi B., Centonze D., Hakansson K., Bernardi G., Greengard P., Fisone G., et al. Loss of bidirectional striatal synaptic plasticity in l-DOPA-induced dyskinesia. Nat Neurosci 2003, 6(5):501-506.
97. Kostowski W., Gajewska S., Bidzinski A., Hauptman M. Papaverine: drug-induced stereotypy and catalepsy and biogenic amines in the brain of the rat. Pharmacol Biochem Behav 1976, 5(1):15-17.
98. Appenzeller S., Schirmacher A., Halfter H., Baumer S., Pendziwiat M., Timmerman V., et al. Autosomal-dominant striatal degeneration is caused by a mutation in the phosphodiesterase 8B gene. Am J Hum Genet 2010, 86(1):83-87.
99. Polli J.W., Kincaid R.L. Expression of a calmodulin-dependent phosphodiesterase isoform (PDE1B1) correlates with brain regions having extensive dopaminergic innervation. J Neurosci 1994, 14(3 Pt 1):1251-1261.
100. Yan C., Bentley J.K., Sonnenburg W.K., Beavo J.A. Differential expression of the 61kDa and 63kDa calmodulin-dependent phosphodiesterases in the mouse brain. J Neurosci 1994, 14(3 Pt 1):973-984.
101. Reed T.M., Repaske D.R., Snyder G.L., Greengard P.C., Vorhees V. Phosphodiesterase 1B knock-out mice exhibit exaggerated locomotor hyperactivity and DARPP-32 phosphorylation in response to dopamine agonists and display impaired spatial learning. J Neurosci 2002, 22(12):5188-5197.
102. Lin D.T., Fretier P., Jiang C., Vincent S.R. Nitric oxide signaling via cGMP-stimulated phosphodiesterase in striatal neurons. Synapse 2010, 64(6):460-466.
103. Stephenson D.T., Coskran T.M., Kelly M.P., Kleiman R.J., Morton D., O'Neill S.M., et al. The distribution of phosphodiesterase 2A in the rat brain. Neuroscience 2012, 226:145-155.
104. Wykes V., Bellamy T.C., Garthwaite J. Kinetics of nitric oxide-cyclic GMP signalling in CNS cells and its possible regulation by cyclic GMP. J Neurochem 2002, 83:37-47.
105. Cho C.H., Cho D.H., Seo M.R., Juhnn Y.S. Differential changes in the expression of cyclic nucleotide phosphodiesterase isoforms in rat brains by chronic treatment with electroconvulsive shock. Exp Mol Med 2000, 32(3):110-114.
106. Siuciak J.A., McCarthy S.A., Chapin D.S., Martin A.N. Behavioral and neurochemical characterization of mice deficient in the phosphodiesterase-4B (PDE4B) enzyme. Psychopharmacology (Berl) 2008, 197(1):115-126.
107. Kurz A., Double K.L., Lastres-Becker I., Tozzi A., Tantucci M., Bockhart V.et al. A53T-alpha-synuclein overexpression impairs dopamine signaling and striatal synaptic plasticity in old mice. PLoS ONE 2010, 5(7):e11464.
108. Reyes-Irisarri E., Perez-Torres S., Mengod G. Neuronal expression of cAMP-specific phosphodiesterase 7B mRNA in the rat brain. Neuroscience 2005, 132(4):1173-1185.
109. Wunder F., Tersteegen A., Rebmann A., Erb C., Fahrig T., Hendrix M. Characterization of the first potent and selective PDE9 inhibitor using a cGMP reporter cell line. Mol Pharmacol 2005, 68(6):1775-1781.
110. Verhoest P.R., Proulx-Lafrance C., Corman M., Chenard L., Helal C.J., Hou X., et al. Identification of a brain penetrant pde9a inhibitor utilizing prospective design and chemical enablement as a rapid lead optimization strategy. J Med Chem 2009, 52:7946-7949.
111. Siuciak J.A., McCarthy S.A., Chapin D.S., Fujiwara R.A., James L.C., Williams R.D., et al. Genetic deletion of the striatum-enriched phosphodiesterase PDE10A: evidence for altered striatal function. Neuropharmacology 2006, 51:374-385.
112. Grauer S.M., Pulito V.L., Navarra R.L., Kelly M.P., Kelley C., Graf R., et al. PDE10A inhibitor activity in preclinical models of the positive, cognitive and negative symptoms of schizophrenia. J Pharmacol Exp Ther 2009, 331:574-590.
113. Schmidt C.J., Chapin D.S., Cianfrogna J., Corman M.L., Hajos M., Harms J.F., et al. Preclinical characterization of selective PDE10A inhibitors: a new therapeutic approach to the treatment of schizophrenia. J Pharmacol Exp Ther 2008, 325:681-690.
114. West A.R., Galloway M.P. Regulation of serotonin-facilitated dopamine release in vivo: the role of protein kinase A activating transduction mechanisms. Synapse 1996, 23:20-27.
115. Kleiman R.J., Kimmel L.H., Bove S.E., Lanz T.A., Harms J.F., Romegialli A., et al. Chronic suppression of PDE10A alters striatal expression of genes responsible for neurotransmitter synthesis, neurotransmission and signaling pathways implicated in Huntington's Disease. J Pharmacol Exp Ther 2011, 336:64-76.
116. Smith S.M., Uslaner J.M., Cox C.D., Huszar S.L., Cannon C.E., Vardigan J.D., et al. The novel phosphodiesterase 10A inhibitor THPP-1 has antipsychotic-like effects in rats and improves cognition in rat and rhesus monkey. Neuropharmacology 2013, 64:215-223.
117. Nishi A., Snyder G.L. Biochemical and behavioral profiles of phosphodiesterase inhibition in dopaminergic transmission. J Pharmacol Sci 2010, 116:6-16.